<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunosuppression with antithymocyte globulin (ATG) or <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSA) can be used to treat the cytopenia associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we identified HLA-DR15, younger age, and shorter duration of red cell transfusion dependence as pretreatment variables that correlate significantly with a response </plain></SENT>
<SENT sid="2" pm="."><plain>Using these pretreatment variables we have devised a simple method to prospectively identify patients with low or high probabilities of response to immunosuppression </plain></SENT>
<SENT sid="3" pm="."><plain>The ability of this system to predict response was confirmed in a separate cohort of 23 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with immunosuppression </plain></SENT>
</text></document>